drugset / Trial / NCT00645853

Long-term Safety in Atrial Fibrillation Patients

NCT00645853

Phase 2 Completed 523 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and systemic embolic events (moderate to high risk patients).

Timeline

Start
2007-10
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ATECEGATRAN METOXIL Small molecule 300 mg Oral
Comparator Warfarin Small molecule